medicalxpress - Patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancers had similar progression-free survival (PFS) whether they were treated with sacituzumab govitecan-hziy (Trodelvy) or standard-of-care chemotherapy as the first treatment af…
#healthcare #pharmaceuticals #drugdevelopment
Saturday, December 13, 2025, 1:21 am / permalink 16912 / 5 stories in 3 months
EPA proposes rollback on ethylene oxide sterilizer emissions (37 min)
Two deaths prompt probe of paid plasma donation clinics in Winnipeg (1 hr)
HIMSS 2026 pushes real‑time data, cloud and interoperability playbook (18 hrs)
Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma (19 hrs)
Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival (22 hrs)
FDA approves leucovorin for rare folate disorder despite autism hype (34 hrs)
NorthFeed Inc.
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.